China’s pharma contractors rally as US supply chain pressures face industry resistance

AI Summary

Chinese pharmaceutical contractors display financial resilience amid US efforts to reduce dependence on China's supply chains. Market optimism stems from resistance within the industry to Washington's push to curb Beijing's role as a global pharma supplier, with companies like WuXi AppTec seeing stock gains.

China’s pharmaceutical contractors are showing financial resilience in the face of Washington’s push to curb reliance on Chinese supply chains. Analysts said investors were bullish because the US government’s recent measures to curb Beijing’s rise as a global pharmaceutical supplier had met resistance from industry players reluctant to give up China’s cost advantages. Hong Kong-listed shares of WuXi AppTec, Asia’s largest provider of contract pharmaceutical research, gained 3 per cent on Monday...